The psychodynamic and pharmacodynamic effects of drugs: A differentiated evaluation of the efficacy of phytotherapy

Phytomedicine

Volumn 7, Issue 1, 2000, Pages 73-81

  Schulz, Volker ^a,b  

^a Arzt für Innere Medizin ^*

^b Akademische Lehrpraxis des Uniklinikums Schleswig Holstein   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; HYPERICUM EXTRACT;

DATA ANALYSIS; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; HUMAN; PHYTOTHERAPY; PRIORITY JOURNAL; PSYCHODYNAMICS; REVIEW;

HYPERICUM;

EID: 0034108844     PISSN: 09447113     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0944-7113(00)80025-2     Document Type: Review

References (21)

1. Balint, M.: Der Arzt, sein Patient und die Krankheit. Stuttgart: Ernst Klett Verlag, 1957.
2. Enserink, M.: Can the Placebo be the cure? Science 284: 238-240, 1999.
3. United States Food and Drug Administration: New Drug Application 18-936 (Fluoxetine), 1988.
4. United States Food and Drug Administration: New Drug Application 20-031 (Paroxetine), 1992.
5. Gauler, T. C., Weihrauch, T. R.: Placebo - ein wirksames und ungefährliches Medikament? Urban & Schwarzenberg, München, 1997.
6. Hänsgen, K. D., Vesper, J., Ploch, M.: Multicenter double-blind study examining the antidepressant effectiveness of the hypericum extract LI 160. Journal of Geriatric Psychiatry and Neurology 7 (suppl. 1): 15-18, 1994.
7. Hänsel, R., Sticher, O., Steinegger, E.: Pharmakognosie - Phytopharmazie. Springer, Berlin 1198-1203, 1999.
8. Hamilton, M.: A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23: 56-61, 1960.
9. Kirsch, I., Sapirstein, G.: Listening to Prozac but hearing placebo: A meta-analysis of antidepressant medication. Prevention & Treatment, 1, Article 0002a. Available on the World Wide Web: http://journals.apa.org/prevention/volume1/pre0010002a.html. 1998.
10. Kurz, A.: Psychopharmaka - Pillen ohne Power? Münch. Med. Wschr./Fortschr. Med.: 141 (33): 17, 1999.
11. Linden, M., Osterheider, M., Schaaf, B. et al.: Fluoxetin in der Anwendung durch niedergelassene Nervenärzte. Münch. Med. Wschr. 134: 836-840, 1992.
12. Maxwell, P. R., Mendall, M. A., Kumar, D.: Irritable bowel syndrome. The Lancet 350: 1691-1695, 1997.
13. Metzker, H., Kieser, M., Hölscher, U.: Wirksamkeit eines Sabal-Urtica-Kombinationspräparates bei der Behandlung der benignen Prostatahyperplasie. (BPH). Urologe (B) 36: 292-300, 1996.
14. Montgomery, S. A.: Alternatives to placebo-controlled trials in psychiatry. European Neuropsychopharmacology 9 (3): 265-269, 1999.
15. Montgomery, S. A.: The failure of placebo-controlled studies. European Neuropsychopharmacology 9 (3): 271-276, 1999.
16. Nickel, J. C.: Placebo therapy of benign prostatic hyperplasia: a 25-month study. British Journal of Urology 81: 383-387, 1998.
17. Nickel J. C., Fradet, Y., Boake, R. C., Pommerville, P. J., Perreault, J., Afridi, S. K., Elhilali, M. M., the PROSPECT Study Group. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled tria, (the PROSPECT Study). Can. Med. Assoc. J. 155 (9): 1251-1259, 1996.
18. Quitkin, F. M.: Placebos, drug effects, and study design: A clinician's guide. Am. J. Psychiatry 156 (6): 829-838, 1999.
19. Weihrauch, T. R., Gauler, T. C.: Placebo - Efficacy and adverse effects in controlled clinical trials. Arzneimittelforschung/Drug Res. 49 (5): 385-393, 1999.
20. Wheatley, D.: Amitriptyline-controlled trial of hypericum extract LI 160. Pharmacopsychiat. 30 (Suppl.): 77-80, 1997.
21. Woelk, H., Burkard, G., Grünwald, J.: Benefits and risks of the Hypericum extract LI 160: Drug monitoring study with 3250 patients. J. Geriatr. Psychiatry Neurol. 7 (Suppl. 1): 34-38, 1994.